Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 22, 2008

Vion Employs French Institute to Carry Out Phase I/II Studies of AML Drug

  • Vion Pharmaceuticals signed on Institut Paoli-Calmettes to conduct a multicenter Phase I/II trial of laromustine as a treatment for acute myelogenous leukemia. The study will enroll patients aged 18-60 with previously untreated AML and a poor prognosis based on their cytogenetic profile. The trial is expected to start this fall and will be conducted at various sites in France.

    After the dose of Cloretazine in combination with daunorubicin and cytarabine is determined in Phase I, the Phase II investigation will determine the complete remission rate. Secondary objectives will be to evaluate the tolerance and toxicities of the combination therapy as well as progression-free survival and overall survival. Patients will be stratified according to age (less than or more than 60 years of age). The prognostic value of various molecular markers will also be studied.